- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT07755189
Night Driving After Trifocal Versus Monofocal IOL Implantation (TriIOL)
Night-Driving Visual Quality and Visual Disturbances After Bilateral Trifocal Versus Monofocal Intraocular Lens Implantation: A Prospective Observational Cohort Study
This prospective observational cohort study will compare night-driving visual difficulty and visual disturbances after bilateral implantation of an Alcon trifocal intraocular lens or an Alcon monofocal intraocular lens in adults undergoing cataract surgery. The type of intraocular lens will be selected by each participant and the treating ophthalmologist as part of routine clinical care, and will not be assigned by the investigators.
Eligible participants must have a valid motor vehicle driving license and a stable history of night driving during the previous 3 months. The primary outcome will be the total score of the Visual Function and Night Driving Questionnaire (VND-Q) at 3 months postoperatively. Secondary assessments will include glare adaptation, self-rated night-driving quality and driving speed, changes in night-driving behavior, visual disturbances, distance, intermediate and near visual acuity, contrast sensitivity, whole-eye aberrations, pupil diameter, defocus performance, reading speed, spectacle independence, and participant satisfaction.
연구 개요
상태
연구 유형
등록 (추정된)
연락처 및 위치
연구 연락처
- 이름: Lei Cai
- 이메일: 1532483480@qq.com
연구 연락처 백업
- 이름: Xuanqiao Lin, Doctor
- 전화번호: +8615088920668
- 이메일: 1532483480@qq.com
연구 장소
-
-
Shanghai Municipality
-
Shanghai, Shanghai Municipality, 중국, 200000
- Eye and ENT Hospital of Fudan University
-
연락하다:
- Xuanqiao Lin
- 전화번호: 15088920668
- 이메일: 1532483480@qq.com
-
-
참여기준
자격 기준
공부할 수 있는 나이
- 성인
- 고령자
건강한 자원 봉사자를 받아들입니다
샘플링 방법
연구 인구
설명
Inclusion Criteria:
- Adults aged 18 to 85 years.
- Scheduled to undergo bilateral phacoemulsification with in-the-bag intraocular lens implantation.
- Both eyes scheduled to receive the same type and model of either an Alcon trifocal intraocular lens or an Alcon monofocal intraocular lens.
- Possession of a valid motor vehicle driving license.
- Stable night-driving behavior during the previous 3 months, with night driving occurring at least twice per month.
- Lens Opacities Classification System III nuclear opalescence grade of 4 or lower in both eyes.
- Expected intraocular lens power between +10.0 D and +36.0 D, inclusive, in both eyes.
- Ability to understand the purpose and procedures of the study and independently complete the VND-Q and visual quality questionnaires.
- Willingness to provide written informed consent and complete the scheduled postoperative follow-up visits.
Exclusion Criteria:
- Corneal endothelial cell density below 1,500 cells/mm² in either eye.
- History of ocular trauma affecting visual function, previous intraocular surgery, or previous corneal refractive surgery in either eye.
- Strabismus, amblyopia, or nystagmus in either eye.
- Any ocular disease that may affect postoperative visual acuity, contrast sensitivity, mesopic visual function, or questionnaire assessment, including but not limited to irregular corneal astigmatism, corneal scar, corneal degeneration, keratoconus, keratitis, corneal dystrophy, uveitis, severe iris atrophy, intraoperative floppy iris syndrome, microphthalmos, macrophthalmos, color vision deficiency, active ocular inflammation, advanced glaucoma or uncontrolled intraocular pressure, macular disease, retinal pigment epithelial disease, diabetic retinopathy, retinal detachment, choroidal detachment, or optic atrophy.
- A high risk of zonular rupture or an contraindication to in-the-bag intraocular lens implantation, including zonular weakness, zonular dialysis, lens subluxation or dislocation, pseudoexfoliation syndrome, Marfan syndrome, posterior capsule rupture, or cyclodialysis.
Severe or unstable systemic disease, including systemic lupus erythematosus or Sjögren syndrome.
- Use of medication judged by the investigator to increase surgical risk or affect visual function, including amiodarone, chlorpromazine, ethambutol, digitalis, or chloroquine.
- Requirement for a combined ocular procedure, including limbal relaxing incisions, intraocular drug injection, retinal laser treatment, or another combined procedure judged inappropriate by the investigator.
- Severe anxiety, depression, or another significant psychiatric disorder.
- Any other condition judged by the investigator to make participation inappropriate.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
코호트 및 개입
그룹/코호트 |
개입 / 치료 |
|---|---|
|
Trifocal IOL Group
Undergo bilateral phacoemulsification and implantation of Alcon trifocal intraocular lens in both eyes
|
AcrySof IQ PanOptix TFNT00 Trifocal Intraocular Lens
|
|
Monofocal IOL Group
Undergo bilateral phacoemulsification and implantation of Alcon monofocal intraocular lens in both eyes
|
Alcon Monofocal Intraocular Lens
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
VND-Q Total Score at 3 Months After Surgery
기간: 3 months after the second-eye surgery
|
The Visual Function and Night Driving Questionnaire (VND-Q) consists of 9 items.
Each item is rated on a 5-point Likert scale from 1, indicating no difficulty, to 5, indicating extreme difficulty.
The total score ranges from 9 to 45, with higher scores indicating greater subjective difficulty during night driving.
|
3 months after the second-eye surgery
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Glare Adaptation Item Score of the VND-Q
기간: 3 months after the second-eye surgery
|
Score of the VND-Q item assessing difficulty adapting to glare from oncoming vehicle headlights.
A higher score indicates greater difficulty with glare adaptation.
|
3 months after the second-eye surgery
|
|
Self-Rated Night-Driving Quality
기간: Baseline and 3 months after the second-eye surgery
|
Participant-reported night-driving quality assessed using a study-specific 5-point rating scale.
Higher or lower scores will be interpreted according to the predefined questionnaire scoring system.
|
Baseline and 3 months after the second-eye surgery
|
|
Self-Rated Night-Driving Speed
기간: Baseline and 3 months after the second-eye surgery
|
Participant-reported assessment of usual night-driving speed using a study-specific 5-point rating scale.
|
Baseline and 3 months after the second-eye surgery
|
|
Percentage of Participants Who Reduce Night Driving
기간: 3 months after the second-eye surgery
|
The number and percentage of participants reporting that they reduced their night-driving frequency after surgery, based on a binary yes-or-no questionnaire item.
|
3 months after the second-eye surgery
|
|
Distance, Intermediate, and Near Visual Acuity
기간: Baseline and 3 months after the second-eye surgery
|
Uncorrected distance visual acuity, uncorrected intermediate visual acuity, uncorrected near visual acuity, corrected distance visual acuity, distance-corrected intermediate visual acuity, and distance-corrected near visual acuity will be measured using logarithm of the minimum angle of resolution units.
Testing distances will be 4 m for distance, 60 cm for intermediate, and 40 cm for near vision.
|
Baseline and 3 months after the second-eye surgery
|
|
Whole-Eye Aberrations
기간: Baseline and 3 months after the second-eye surgery
|
Whole-eye optical aberrations measured using the same wavefront aberrometry device and standardized testing parameters for all participants.
|
Baseline and 3 months after the second-eye surgery
|
|
Visual Disturbance Questionnaire Score
기간: Baseline and 3 months after the second-eye surgery
|
Participant-reported frequency or severity of glare, halos, starbursts, and other visual disturbances assessed using a standardized visual quality questionnaire.
|
Baseline and 3 months after the second-eye surgery
|
공동 작업자 및 조사자
스폰서
수사관
- 수석 연구원: Jin Yang, Fudan University
연구 기록 날짜
연구 주요 날짜
연구 시작 (추정된)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
기타 연구 ID 번호
- TriIOL-2026
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .